文献速递胸部肿瘤

非小细胞肺癌中的EGFR致癌突变通过上调CD47损害巨噬细胞吞噬作用并介导先天免疫逃逸

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
PubMed 文献 · J Thorac Oncol · 2024-03-27

本研究探讨EGFR突变非小细胞肺癌的免疫逃逸机制。通过患者和细胞系数据筛选及体内外实验,发现EGFR突变通过ERK/c-Myc和AKT/NF-κB通路上调CD47表达,损害巨噬细胞吞噬;CD47阻断可恢复吞噬并增强肿瘤杀伤,与EGFR酪氨酸激酶抑制剂联用显示 additive 抗肿瘤活性。

要点

  • EGFR突变非小细胞肺癌中CD47为与EGFR活化最相关的免疫检查点。
  • EGFR突变通过ERK/c-Myc和AKT/NF-κB通路上调CD47转录。
  • CD47阻断恢复巨噬细胞吞噬,与EGFR酪氨酸激酶抑制剂联用显示 additive 抗肿瘤活性。

核心结论

  • EGFR敏感突变通过上调CD47促进非小细胞肺癌逃逸先天免疫攻击。
  • 包含CD47阻断的联合治疗在转化为更有效治疗EGFR突变非小细胞肺癌方面具有较大希望。

研究设计与样本

  • 使用患者水平和细胞系水平数据集筛选并相互验证EGFR突变与免疫检查点相关基因 panel 的关联。
  • 通过体外调控EGFR信号通路,并采用免疫印迹、定量聚合酶链反应、流式细胞术、免疫荧光染色和染色质免疫沉淀阐明调控机制。
  • 使用免疫健全和免疫缺陷小鼠模型进行不同治疗策略的体内研究。

主要发现

  • 在所有筛查的免疫检查点中,CD47成为与EGFR活化最相关的候选分子。
  • EGFR突变组成性激活下游ERK和AKT通路,分别上调转录因子c-Myc和NF-κB,两者均与CD47启动子区结合并主动转录该「别吃我」信号。
  • 在非小细胞肺癌细胞系模型中引入EGFR致敏突变后观察到巨噬细胞吞噬作用受损,而CD47阻断在体外和体内模型中均恢复吞噬能力并增强肿瘤细胞杀伤。
  • 在免疫健全和适应性免疫缺陷小鼠模型中,抗CD47抗体与EGFR酪氨酸激酶抑制剂联合对比任一单药显示 additive 抗肿瘤活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFR-mutated NSCLC is characterized by an immunosuppressive microenvironment that confers limited clinical effectiveness to anti-PD-1 or PD-L1 antibodies. Despite the discouraging outcomes of immunotherapy, novel immune checkpoints are constantly emerging, among which the specific vulnerability for therapeutic intervention in the context of EGFR-mutated NSCLC remains unresolved. METHODS: Data sets of patient- and cell line-levels were used for screening and mutual validation of association between EGFR mutation and a panel of immune checkpoint-related genes. Regulatory mechanism was elucidated through in vitro manipulation of EGFR signaling pathway and evaluated by immunoblot analysis, quantitative polymerase chain reaction, flow cytometry, immunofluorescence staining, and chromatin immunoprecipitation. In vivo investigation of different therapeutic strategies were conducted using both immunocompetent and immunodeficient mouse models. RESULTS: Among all screened immune checkpoints, CD47 emerged as the candidate most relevant to EGFR activation. Mechanistically, EGFR mutation constitutively activated downstream ERK and AKT pathways to respectively up-regulate the transcriptional factors c-Myc and NF-κB, both of which structurally bound to the promotor region of CD47 and actively transcribed this "don't eat me" signal. Impaired macrophage phagocytosis was observed on introduction of EGFR-sensitizing mutations in NSCLC cell line models, whereas CD47 blockade restored the phagocytic capacity and augmented tumor cell killing in both in vitro and in vivo models. Remarkably, the combination of anti-CD47 antibody with EGFR tyrosine kinase inhibitor revealed an additive antitumor activity compared with monotherapy of either antitumor agent in both immunocompetent and adaptive immunity-deficient mouse models. CONCLUSIONS: EGFR-sensitizing mutation facilitates NSCLC's escape from innate immune attack through up-regulating CD47. Combination therapy incorporating CD47 blockade holds substantial promise for clinical translation in developing more effective therapeutic approaches against EGFR-mutant NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hu LY, Zhuang WT, Chen MJ, et al. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47. J Thorac Oncol. 2024. PMID: 38553005. doi:10.1016/j.jtho.2024.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。